Blood Pressure Lowering Effect of Supplementation With Korea Red Ginseng Associated With Reductions in Circulating Lp-PLA2 Activity and Lysophospatidylcholines and an Increase in Dihydrobiopterin in Prehypertensive Subjects

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02326766

Enrollment

Registered

2014-12-29

Start date

2011-11-30

Completion date

2012-03-31

Last updated

2014-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prehypertension

Brief summary

This study evaluated effects of red ginseng consumption on blood pressure (BP) and fasting plasma metabolomes.

Detailed description

A randomized, double-blind, placebo-controlled study was conducted on nonobese, nondiabetic and prehypertensive subjects. Over a 12 week test period, the red ginseng group (n=31) consumed 10 capsules (total 5g) daily containing red ginseng, while the placebo group (n=31) consumed the same product without red ginseng. Fasting plasma metabolomes were profiled using UPLC-LTQ-Orbitrap mass spectrometry.

Interventions

DIETARY_SUPPLEMENTKRG

5g Korea red ginseng (KRG)

DIETARY_SUPPLEMENTPlacebo

5g placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Inclusion criteria

* nondiabetic, nonobese and prehypertensive subjects with blood pressures ranging 120 - 139 mmHg (systolic) or 80-89 mmHg (diastolic) were enrolled in this study.

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
changes from baselilne in blood pressure	12 week

Secondary

Measure	Time frame
changes from baseline in plasma metabolites	12 week

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026